We use our NuMimetic technology to discover molecules that bind
effectively and specifically to certain regulatory sites, called
nucleotide binding sites, residing on certain enzymes, a type
of protein. By targeting these enzymes we are in turn able to
target the metabolic pathways in the liver that play a role
in various diseases such as diabetes and/or hyperlipidemia.
We have developed a library of unique molecules, known as nucleotide
mimetics, and have used this library to discover compounds that
we believe have the potential to treat metabolic diseases. We
used our NuMimetic technology to discover CS-917 and MB07803,
and we are also using it in certain of our advanced research
programs including the AMPK discovery project we are conducting
with Merck.
